Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's disease

21 Mar 2025

Abstract excerpt

INTRODUCTION: Alzheimer disease (AD)-modifying therapies are approved for treatment of early-symptomatic AD. Autosomal dominant AD (ADAD) provides a unique opportunity to test therapies in presymptomatic individuals. METHODS: Using data from the Dominantly Inherited Alzheimer Network (DIAN), sample sizes for clinical trials were estimated for various cognitive, imaging, and CSF outcomes. Sample sizes were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Amyotrophic Lateral Sclerosis Research
Share to Dementia and Cognitive Impairment Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40118731
DOI: 10.1016/j.tjpad.2025.100133

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sample size estimates for biomarker-based outcome measures in clinical trials in autosomal dominant Alzheimer's diseasePMID 40118731Read ↗

Dominantly Inherited Alzheimer Network: facilitating research and clinical trialsSemantic proximity Read ↗

Developing an international network for Alzheimer’s research: the Dominantly Inherited Alzheimer NetworkSemantic proximity Read ↗

Use of preclinical Alzheimer’s disease trajectories for clinical trial designSemantic proximity Read ↗

Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging InitiativeSemantic proximity Read ↗

15 Years of Longitudinal Genetic, Clinical, Cognitive, Imaging, and Biochemical Measures in DIANSemantic proximity Read ↗

Discovery and validation of autosomal dominant Alzheimer's disease mutations.Semantic proximity Read ↗

Positron emission tomography and magnetic resonance imaging methods and datasets within the Dominantly Inherited Alzheimer Network (DIAN).Semantic proximity Read ↗

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read ↗

Clinical trials in predementia stages of Alzheimer disease.Semantic proximity Read ↗

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.Semantic proximity Read ↗

Eligibility for Anti-Amyloid Therapies in Patients With Biomarker-Confirmed Atypical Alzheimer Disease Phenotypes.Semantic proximity Read ↗

Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.